Physician profile
William D Weeks
NPI 1245237882
$1,586.90
in general payments reported to CMS, 2019-2025
24 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $176 · 2021: $224 · 2022: $620 · 2023: $109 · 2024: $143 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $262.03 | 2022 | |
| Organogenesis INC. | $191.45 | 2022-2024 | Puraply |
| Amgen INC. | $165.26 | 2022-2025 | Repatha, Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $128.37 | 2024 | Voquezna |
| Amag Pharmaceuticals, INC. | $118.24 | 2020 | |
| Abbvie INC. | $95.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.75 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $66.24 | 2019-2021 | |
| Esperion Therapeutics, INC. | $56.81 | 2021-2022 | |
| Organon LLC | $53.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $52.56 | 2019-2020 | |
| Pfizer INC. | $48.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $34.91 | 2021 | |
| Amarin Pharma, INC. | $20.17 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $19.87 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.86 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.17 | 2019 | |
| Galderma Laboratories, L.P. | $17.65 | 2021 | |
| Lilly USA, LLC | $15.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.86 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.13 | 2023 | Nuzyra |
| Mylan Specialty L.P. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.